Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 21Xarelto

02 1XareltoTM

PharmaCompass

01

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 5,461

2019 Revenue in Millions : 4,991

Growth (%) : 9

Company Banner

02

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 5,213

2020 Revenue in Millions : 5,461

Growth (%) : 5

Company Banner

03

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 4,742

2021 Revenue in Millions : 5,213

Growth (%) : -9

Company Banner

04

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 4,428

2022 Revenue in Millions : 4,742

Growth (%) : -10

Company Banner

05

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2024 Revenue in Millions : 3,665

2023 Revenue in Millions : 4,428

Growth (%) : -17

Company Banner

06

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Anticoagulants

Currency : USD

2015 Revenue in Millions : 1,847

2014 Revenue in Millions : 2,477

Growth (%) : 34%

Company Banner

07

Brand Name : XareltoTM

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Anticoagulants

Currency : USD

2014 Revenue in Millions : 76.90%

2013 Revenue in Millions :

Growth (%) :

Company Banner

08

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2017 Revenue in Millions : 4,090

2016 Revenue in Millions : 3,631

Growth (%) : 13

Company Banner

09

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2018 Revenue in Millions : 4,103

2017 Revenue in Millions : 3,727

Growth (%) : 10%

Company Banner

10

Brand Name : Xarelto

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Rivaroxaban

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2016 Revenue in Millions : 3,104

2015 Revenue in Millions : 2,387

Growth (%) : 30

Company Banner